 |
|
Chronic diarrhea unresponsive to conventional medication: Are you taking lansoprazole?
May 14, 2009Lansoprazole is a proton pump inhibitor which powerfully suppresses gastric acid production and is widely prescribed for chronic use in gastroesophageal reflux disease. Lansoprazole uncommonly causes chronic watery diarrhea unresponsive to conventional medication as a symptom of collagenous colitis. This association has recently been reported and is not widely known. Correct diagnosis and treatment without this knowledge is impossible. Discontinuation of lansoprazole results in the prompt resolution of diarrhea.
A 70-year old woman developed watery diarrhea 4 to 9 times a day. She had interstitial pneumonia at 67 and reflux esophagitis at 70. Lansoprazole 30 mg/day had been prescribed for reflux esophagitis for nearly 6 months. Lansoprazole was withdrawn due to its possible side effect of diarrhea. Colonoscopy disclosed diffuse cloudiness of the mucosa which suggested ulcerative colitis. Consequently sulfasalazine 2 g/day was started. The patient's diarrhea dramatically disappeared the following day. However, biopsy specimens showed subepithelial collagenous thickening and infiltration of inflammatory cells in the lamina propria confirming the diagnosis of collagenous colitis.
One month after sulfasalazine therapy was initiated, both colonoscopic and histological abnormalities resolved completely. Five months later the diarrhea recurred. The findings on colonoscopy and histology were the same as before confirming a diagnosis of collagenous colitis relapse. The author found that the patient had been taking lansoprazole again three months ahead of the recent episode of diarrhea. Withdrawal of lansoprazole promptly resolved the diarrhea. Endoscopic and histological abnormalities were also completely resolved similar to the first episode. Retrospectively, the date of commencement of sulfasalazine and the discontinuation of lansoprazole in the first episode was found to be the same. The author concluded that the patient had lansoprazole-associated collagenous colitis.
This case is reported by Dr. Chiba and his colleagues in the Division of Gastroenterology, Nakadori General Hospital, Akita, Japan and it is to be published on May 7, 2009 in the World Journal of Gastroenterology.
A doctor and a patient can easily recognize the side effects of medication taken recently. However, symptoms occurring in chronic use of a drug such as the present case, diarrhea 6 months after taking lansoprazole, it might be difficult to suspect this side effect. Therefore, knowledge is important: lansoprazole in chronic use can cause chronic diarrhea as a symptom of collagenous colitis.
World Journal of Gastroenterology
This case is reported by Dr. Chiba and his colleagues in the Division of Gastroenterology, Nakadori General Hospital, Akita, Japan and it is to be published on May 7, 2009 in the World Journal of Gastroenterology.
A doctor and a patient can easily recognize the side effects of medication taken recently. However, symptoms occurring in chronic use of a drug such as the present case, diarrhea 6 months after taking lansoprazole, it might be difficult to suspect this side effect. Therefore, knowledge is important: lansoprazole in chronic use can cause chronic diarrhea as a symptom of collagenous colitis.
World Journal of Gastroenterology
Lansoprazole Current Events and Lansoprazole News RSSStudy shows benefits of anti-clotting medications reduced by common heartburn drugs
The anti-clotting action of the medication clopidogrel (Plavix) can be compromised by common drugs for the treatment of heartburn and ulcers resulting in a roughly 50% increase in the combined risk of hospitalization for heart attack, stroke and other serious cardiovascular illnesses.
Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease
In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.
Is esomeprazole the best choice for reflux esophagitis patients?
In patients with gastroesophageal reflux disease (GERD), esomeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the other proton pump inhibitors( PPIs ).
Proton pump inhibitors increase risk of heart attacks for patients on common cardiac drug
Patients taking the common cardiac drug clopidogrel following a heart attack are at a significantly higher risk of a recurrence if they are also taking widely used acid-lowering medications called proton pump inhibitors, a new study published online in CMAJ has found (http://www.cmaj.ca/cgi/rapidpdf/cmaj.082001).
Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
Combined results from two Phase 3 studies presented at the American College of Gastroenterology Annual Scientific Meeting (ACG) in Orlando, Fla., demonstrated that TAK-390MR resulted in higher healing rates than lansoprazole among patients with more severe grades of erosive esophagitis (EE).
What is the best strategy for treating Helicobacter pylori?
The most popular treatment for H pylori is triple therapy but resistance to Clarithromycin is reducing its effectiveness.
Common antacids could help keep gingivitis at bay
Chemicals commonly used to treat heartburn also display fighting power against the oral bacteria linked with gum disease, according to researchers at the University of Rochester Medical Center and Göteborg University in Sweden.
GASTRIC REFLUX COULD BE TEMPERED BY H PYLORI ERADICATION
Eradication of a bacterium present in the stomach could reduce the frequency of a common gastric disorder characterised by heartburn and chest pain, conclude authors of a study in this week's issue of THE LANCET. There is little information on the effects of Helicobacter pylori eradication in patients with a primary diagnosis of gastro-oesophageal reflux disease (GORD). Werner Schwizer and colleagues from University Hospital, Zurich, Switzerland, investigated the effect of H pylori eradication in this group of patients. 70 patients with GORD took part in a randomised, placebo-controlled, double-blind study. Patients were divided into three groups, with all patients receiving lansoprazole (to
Gut Reactions in Europe and US
Heartburn disease: A story of sleep, sex and suffering 22 May 2001 – Mölndal, Sweden – Eating, sleeping, sport and sex - activities that are supposed to be part of life’s pleasures are for a large group of people, being disrupted on a daily basis by an unlikely culprit – heartburn. More than 50 million Europeans (imagine the entire populations of Sweden, Denmark, Norway, Finland, Ireland, Netherlands and Austria combined1) suffer from heartburn disease, a condition in which stomach acid flows back into the esophagus causing an unpleasant burning pain and acid taste. Results of a pan-European survey, involving more than 5000 people in France, Germany, Italy, Sweden a
More Lansoprazole Current Events and Lansoprazole News Articles
|
Lansoprazole found safe for infants with GERD.(Digestive Disorders)(Gastroesophageal reflux disease ): An article from: Family Practice News by Jane Salodof MacNeil (Author) This digital document is an article from Family Practice News, published by International Medical News Group on September 15, 2006. The length of the article is 701 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Lansoprazole found safe for infants with GERD.(Digestive Disorders)(Gastroesophageal reflux disease ) Author: Jane Salodof MacNeil Publication: Family Practice News (Magazine/Journal) Date: September 15, 2006 Publisher: International Medical News Group Volume: 36 Issue: 18 Page: 40(1) Distributed by Thomson... | |
|
Lansoprazole Beats Ranitidine for NSAID-Related Gastric Ulcers.(Brief Article): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on March 15, 2001. The length of the article is 3759 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Lansoprazole Beats Ranitidine for NSAID-Related Gastric Ulcers.(Brief Article) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: March 15, 2001 Publisher: International Medical News Group Volume: 31 Issue: 6 Page: 26 Article Type: Brief Article Distributed by Thomson... | |
|
Esomeprazole effective in gastric ulcer healing: esomeprazole once a day more effective than twice-daily ranitidine, matches twice-daily lansoprazole.(Digestive ... An article from: Family Practice News by Sherry Boschert (Author) This digital document is an article from Family Practice News, published by International Medical News Group on October 1, 2004. The length of the article is 817 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Esomeprazole effective in gastric ulcer healing: esomeprazole once a day more effective than twice-daily ranitidine, matches twice-daily lansoprazole.(Digestive Disorders) Author: Sherry Boschert Publication: Family Practice News (Magazine/Journal) Date: October 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 19 Page:... | |
|
Add PPI to NSAID therapy; avoid peptic ulcer: esomeprazole and lansoprazole.(Clinical Rounds)(proton pump inhibitors): An article from: Family Practice News by Jeff Evans (Author) This digital document is an article from Family Practice News, published by International Medical News Group on January 1, 2004. The length of the article is 612 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Add PPI to NSAID therapy; avoid peptic ulcer: esomeprazole and lansoprazole.(Clinical Rounds)(proton pump inhibitors) Author: Jeff Evans Publication: Family Practice News (Magazine/Journal) Date: January 1, 2004 Publisher: International Medical News Group Volume: 34 Issue: 1 Page: 37(1) Distributed by Thomson... | |
 |
Lansoprazole: Webster's Timeline History, 1991 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Lansoprazole," including when used in literature (e.g. all authors that might have Lansoprazole in their name). As such, this book represents the largest compilation of timeline events associated with Lansoprazole when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social... |
|
Asthmatics with reflux benefit from proton-pump inhibition. (High-Dose Lansoprazole).: An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on December 15, 2002. The length of the article is 551 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Asthmatics with reflux benefit from proton-pump inhibition. (High-Dose Lansoprazole). Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: December 15, 2002 Publisher: International Medical News Group Volume: 35 Issue: 24 Page: 10(1) Distributed by Thomson... | |
|
PPIs may reduce NSAID-related ulcers and upper GI symptoms: esomeprazole and lansoprazole.(Gastroenterology): An article from: Internal Medicine News by Jeff Evans (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2004. The length of the article is 612 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: PPIs may reduce NSAID-related ulcers and upper GI symptoms: esomeprazole and lansoprazole.(Gastroenterology) Author: Jeff Evans Publication: Internal Medicine News (Magazine/Journal) Date: January 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 2 Page: 42(1) Distributed by Thomson... | |
|
Proton-pump inhibitor helps asthma patients with reflux. (Improved Quality of Life).(lansoprazole): An article from: Family Practice News by Bruce Jancin (Author) This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2003. The length of the article is 930 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Proton-pump inhibitor helps asthma patients with reflux. (Improved Quality of Life).(lansoprazole) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: February 1, 2003 Publisher: International Medical News Group Volume: 33 Issue: 3 Page: 30(1) Distributed by Thomson... | |
![Degradation of lansoprazole and omeprazole in the aquatic environment [An article from: Chemosphere]](http://ecx.images-amazon.com/images/I/51M6G4MFGFL._SL160_.jpg) |
Degradation of lansoprazole and omeprazole in the aquatic environment [An article from: Chemosphere] by M. DellaGreca (Author), M.R. Iesce (Author), L. Previtera (Author), M Rubino (Author) This digital document is a journal article from Chemosphere, published by Elsevier in 2006. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser. Description: Lansoprazole and omeprazole degrade in water leading to sulfides, benzimidazolones and a red complex material. Degradation is accelerated in acid medium and by solar simulator irradiation. Benzimidazoles, dianilines and pyridines have also been identified. |
|
Lansoprazole: GORD (Drugs in Context) by A.Pali S. Hungin (Author), Susan Chambers (Author), Richard Stevens (Author) |
| © 2009 BrightSurf.com |